Hengrui Pharmaceuticals Licenses SHR2554 to Treeline Biosciences
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced a licensing agreement with US-based Treeline Biosciences,...
CSPC Pharmaceutical Licenses ADC SYS6002 to Corbus Pharmaceuticals
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a licensing agreement with Massachusetts-based Corbus...
Mingche Biotechnology Secures Pre-Series A Funding for Medical Device Innovation
China-based high-value medical device firm Mingche Biotechnology (Suzhou) Co., Ltd has reportedly raised “tens of...
Dessight Biomedical Secures Pre-Series A Funding for Ophthalmic Innovations
Hangzhou Dessight Biomedical has reportedly raised “tens of millions” of renminbi in a Pre-Series A...
Luye Pharma Initiates Phase I Study for BA1106, a CD25 Monoclonal Antibody
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
Zelgen’s ZGGS15 Accepted for NMPA Review as First Global BsAb Filing
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that a clinical trial filing for...
Kintor’s GT20029 Shows Positive Results in US Phase I Study for AGA and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive topline data from a Phase I...
Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for Breakthrough Designation
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that its SHR-A1811, an HER2 targeted antibody-drug...
EOC Pharma’s CDK7 Inhibitor EOC237 Accepted for CDE Review
EOC Pharma, a biotech operating out of the US and China, has announced that a...
Joincare’s Generic Seretide Accepted for NMPA Review
China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing...
Nona Biosciences Partners with Mythic Therapeutics for Next-Gen ADCs
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership...
Everest Medicines’ Nefecon Included in South Korea’s GIFT Program
China-based Everest Medicines (HKG: 1952) has announced that South Korea’s Ministry of Food and Drug...
Haohai Bio Acquires Additional Stake in SZNIMO for Ophthalmic Expansion
China-based Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826, SHA: 688366), a leading biomaterial firm...
Hinova’s HP530S Accepted for NMPA Review as FAK Inhibitor for Solid Tumors
China-based biopharma Hinova Pharmaceuticals (SHA: 688302) has announced that a clinical trial filing for its...
AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth
UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4...
Qilu Pharmaceutical’s QLS12004 Gains Tacit Clinical Trial Approval
The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical...
Sino Biopharmaceutical Terminates IPO Pre-Listing Process for STAR Board
Sino Biopharmaceutical Ltd (HKG: 1177) has announced the decision to terminate the pre-listing process for...
Shanghai Pinnacles Partners with Sysmex for Biochemical Immune Diagnosis Solutions
China’s Shanghai Pinnacles Medical Technology Co., Ltd has struck a partnership with Japan-based Sysmex Corporation,...
GenScript ProBio Partners with Bio Immunitas for hRPP Platform
Nanjing-based GenScript ProBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), has formed a...
ImmVira’s MVR-T3011 IT Shows Efficacy in Melanoma Treatment
Shenzhen-based biopharma ImmVira has revealed that its first intra-tumoral injection oncolytic virus (OV) product, MVR-T3011...